8-K/A: Turnstone Biologics Amends Merger Agreement with XOMA, Clarifying Contingent Value Rights and Support Terms

Turnstone Biologics Corp. has filed an amendment to its merger agreement with XOMA Royalty Corporation, primarily to include the full forms of the Contingent Value Rights Agreement and Tender and Support Agreement, detailing the $0.34 cash per share plus CVR offer.

Summary

• Turnstone Biologics Corp. (the 'Company') is being acquired by XOMA Royalty Corporation ('Parent') through a tender offer and subsequent merger with Parent's subsidiary, XRA 3 Corp. ('Merger Sub').
• The offer price for each share of Company Common Stock is $0.34 in cash (the 'Cash Amount') plus one contingent value right (a 'CVR').
• The CVR represents the right to receive potential future cash payments based on 'CVR Proceeds,' which include a 'Legacy Receivable Amount' and any 'Net Cash Excess,' minus any 'Net Cash Shortfall.'
• The 'Legacy Receivable Amount' is defined as net tax receivables from Canadian federal/provincial tax authorities (up to $850,000, excluding a $55,610 Quebec SR&ED amount) and security deposit returns from a sublease with Medivis, Inc. (up to $260,000).
• The 'Net Cash Excess' is the amount by which the 'Final Net Cash' (recalculated 180 days post-merger) exceeds the 'Closing Net Cash' (estimated at Offer Closing Time), while 'Net Cash Shortfall' is the inverse.
• The 'Closing Net Cash' calculation includes the Company's cash, cash equivalents, marketable securities, prepaid expenses, receivables, and deposits, minus consolidated short-term and long-term contractual obligations, Transaction Expenses, and Estimated Costs Post-Merger Closing.
• A key condition for the offer is that the 'Closing Net Cash' must be at least $2,000,000.
• The 'CVR Period' for potential payments extends from the Closing Date to one year thereafter.
• Company Stock Options outstanding at the Effective Time will be canceled without consideration.
• Company Restricted Stock Units outstanding will vest in full immediately prior to the Offer Closing Time and be canceled at the Effective Time, with holders receiving the Cash Amount ($0.34) and one CVR per unit.
• The Company's 2023 Employee Stock Purchase Plan (ESPP) will be terminated, with no new offering periods commencing after the Agreement Date.
• The merger will be effected under Section 251(h) of the Delaware General Corporation Law (DGCL), meaning no stockholder vote is required after the tender offer is consummated.
• The Company Board unanimously recommended that stockholders accept the Offer and tender their shares.
• Certain stockholders have entered into Tender and Support Agreements, committing to tender their shares into the Offer.
• The Company is permitted to undertake 'Permitted Dispositions' (sales, transfers, licenses of assets) prior to the Offer Closing Time, including the Asset Purchase Agreement with Lee Moffitt Cancer Center and Research Institute, Inc., whose obligations Parent will assume.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the merger provides an exit for shareholders, the cash consideration is very low, and the CVR is highly speculative and illiquid. The cancellation of stock options without consideration and the explicit 'Wind-Down Process' for the company's operations are significant negative factors, indicating a distressed sale rather than a strong growth acquisition.

Positives

• The merger provides a clear exit strategy for Turnstone Biologics shareholders, particularly given the company's ongoing 'Wind-Down Process'.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential future upside based on specific financial outcomes (tax receivables, security deposit returns, and net cash excess), providing a speculative component beyond the initial cash payment.
• The Company Board unanimously determined the transaction to be fair and in the best interests of the Company and its stockholders, recommending the offer.
• The merger structure under DGCL Section 251(h) streamlines the process, eliminating the need for a separate stockholder meeting and vote after the tender offer.

Negatives

• The cash component of the offer price is very low at $0.34 per share, indicating a minimal immediate cash return for shareholders.
• All outstanding Company Stock Options will be canceled without consideration, which is a significant negative for option holders.
• The CVRs are highly speculative, with no assurance that any payments will be made, and they are non-transferable except for limited 'Permitted CVR Transfers,' limiting liquidity.
• The company is undergoing a 'Wind-Down Process' of its operations and R&D activities, suggesting a cessation of active business and potential job losses.
• The Company's 2023 Employee Stock Purchase Plan (ESPP) will be terminated, impacting employee benefits.

Risks

• The CVRs are highly speculative, and there is no assurance that Holders will receive any payments under the CVR Agreement, as payments are contingent on specific financial outcomes (Legacy Receivable Amount, Net Cash Excess).
• The CVRs are generally non-transferable, limiting liquidity and the ability of holders to realize value from them prior to any potential payment.
• The 'Closing Net Cash' condition requires a minimum of $2,000,000; if the final determination falls below this, the offer may not be consummated, leading to uncertainty.
• The 'Wind-Down Process' of the Company's operations and R&D activities carries inherent risks related to managing ongoing obligations, closing clinical studies, and potential unforeseen costs.
• Potential for stockholder litigation challenging the transaction, which could incur costs and delays, although the Company will provide Parent an opportunity to review and comment on filings related to such proceedings.

Future Outlook

The document outlines the definitive terms for the acquisition of Turnstone Biologics by XOMA, including a cash component and a contingent value right (CVR) that offers potential future payments based on specific financial outcomes. The Company is explicitly undergoing a 'Wind-Down Process' of its operations and research and development activities, indicating a cessation of its independent business functions post-merger. The future outlook for the company as an independent entity is dissolution into the acquirer's structure, with any future value for former shareholders tied to the highly speculative CVRs.

Management Comments

• Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer and Director, signed the report on behalf of Turnstone Biologics Corp.

Industry Context

This acquisition represents a strategic move by XOMA Royalty Corporation, a company focused on royalty streams, to acquire Turnstone Biologics, a biotechnology firm. The low cash offer combined with a CVR structure is common in biotech M&A, especially for companies with pipeline assets or specific financial receivables but limited ongoing operational value. The 'Wind-Down Process' suggests that Turnstone Biologics' primary value lies in its intellectual property, remaining assets, and specific financial receivables rather than its continued operational activities. This type of transaction allows the acquirer to potentially monetize specific assets or future revenue streams while minimizing exposure to ongoing operational costs and risks associated with a winding-down entity. It reflects a trend where larger entities or royalty companies acquire smaller biotech firms for specific value propositions rather than full integration of their R&D or commercial operations.

Comparison to Industry Standards

• The use of a Contingent Value Right (CVR) in a biotech acquisition is a common mechanism to bridge valuation gaps between buyer and seller, particularly when the value of certain assets (like future royalties, specific receivables, or clinical milestones) is uncertain. For example, similar CVR structures have been seen in acquisitions like Sanofi's acquisition of Principia Biopharma or Roche's acquisition of Spark Therapeutics, though the underlying assets and payment triggers vary significantly.
• The low cash component of $0.34 per share, coupled with the CVR, suggests that Turnstone Biologics' current operational value or pipeline prospects, excluding the specific CVR triggers, were deemed minimal by the acquirer. This contrasts with acquisitions of companies with late-stage clinical assets or approved products, which typically command higher upfront cash premiums, such as Gilead's acquisition of Immunomedics ($21 billion) or Bristol Myers Squibb's acquisition of Celgene ($74 billion), where the acquired companies had significant commercial or near-commercial assets.
• The explicit mention of a 'Wind-Down Process' for Turnstone Biologics' operations and R&D activities indicates that this is an asset-focused acquisition rather than a strategic merger for ongoing operational synergy. This is distinct from typical biotech mergers where the acquiring company intends to integrate and continue the R&D efforts of the acquired entity, as seen in Pfizer's acquisition of Seagen or Amgen's acquisition of Horizon Therapeutics, which were driven by pipeline expansion and market access.
• The assumption of the Moffitt Asset Purchase Agreement by Parent aligns with industry practices where acquirers take on specific contractual obligations related to valuable intellectual property or research collaborations from the acquired entity.

Management Changes

Corporate Governance

Legal Proceedings

• The Company will provide Parent an opportunity to review and comment on material filings or responses in connection with any Proceedings commenced or threatened by stockholders relating to the transaction.
• The Company will not settle any such proceedings without Parent's consent, unless fully covered by insurance (excluding deductible) or solely related to additional Schedule 14D-9 disclosure and not imposing business restrictions.

Related Party Transactions

• No event has occurred since April 22, 2024 (date of proxy statement) that would be required to be reported by the Company pursuant to Item 404 of Regulation S-K, except as set forth in Company SEC Documents filed prior to the Agreement Date.

Stakeholder Impact

• **Shareholders**: Will receive $0.34 cash per share plus one CVR, which offers speculative future payments. Shareholders who entered into Support Agreements are committed to tendering their shares. The CVRs are illiquid, limiting immediate monetization of potential future value.
• **Employees**: Company Stock Options will be canceled without consideration, negatively impacting option holders. Company Restricted Stock Units will vest and convert to cash and CVRs. The Company's ESPP will be terminated. The 'Wind-Down Process' implies significant job reductions as operations cease.
• **Management/Directors**: Existing indemnification rights and D&O insurance will be maintained for six years post-merger, providing protection against liabilities for past acts.
• **Creditors/Suppliers**: The 'Wind-Down Process' and assumption of certain liabilities by Parent (e.g., Moffitt Asset Purchase Agreement) will impact existing contractual relationships, with the goal of settling obligations as part of the wind-down.

Next Steps

• Parent to commence the tender offer as promptly as practicable, but no later than ten Business Days after the Agreement Date (June 26, 2025).
• Company to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC on the date the Offer Documents are filed or as promptly thereafter as practicable.
• Parent to irrevocably accept for payment and pay for tendered shares within three Business Days after the expiration of the Offer, assuming conditions are met.
• Merger Closing to occur as soon as practicable following the Offer Closing Time, but no later than the second Business Day following satisfaction or waiver of conditions.
• Company to obtain and fully pay premium for D&O Tail Policies at or prior to the Effective Time.
• Company to terminate or withdraw from participation in 401(k) plans and other ERISA plans effective the day immediately preceding the Effective Time.
• Surviving Corporation to cause the Company's securities to be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time, and in any event no more than ten days after the Merger Closing Date.
• Parent to ensure Purchaser and Surviving Corporation perform all obligations under the Agreement.
• Parent to assume all obligations, duties, and covenants under the Moffitt Asset Purchase Agreement effective as of the Offer Closing Time.
• Representative to distribute any remaining Expense Fund to the Rights Agent for further distribution to Holders after it is no longer required.

Key Dates

Recommendation

Keywords

Merger Agreement, Tender Offer, Contingent Value Right, CVR, XOMA Royalty Corporation, Turnstone Biologics Corp., TSBX, Biotechnology, Pharmaceutical, Acquisition, SEC Filing, 8-K/A, Corporate Action, Wind-Down Process, Asset Sale, Corporate Governance